The Adoption Mirage
Indian genomics founders celebrate when a hospital orders 100 tests. They see revenue. They see traction. They raise their next round on this.
But that hospital never orders again.
They ordered once because a doctor was curious. Or because a patient was insistent. Or because it was discounted. This is not PMF. This is a transaction.
PMF in genomics is when the same customer—hospital, diagnostic chain, direct-to-consumer app—comes back monthly. When testing becomes part of their protocol. When they can't operate without your test.
We saw this in diagnostic chains. PathCare, Thyrocare, diagnostic networks—they repeat test. They build workflows around a test. They integrate it into their standard panel. That's PMF.
The Economics Reality
Sequencing costs in India have fallen. FASTQ generation is ₹800-1200 per sample now. Bioinformatics pipelines are ₹200-400. Variant calling and reporting, ₹300-500.
Total cost of goods: ₹1300-2100 for a clinically useful genome test.
If you're selling at ₹5000, your margin looks healthy. But it collapses under real pressure: customer acquisition cost, clinical validation, regulatory overhead, support.
When a founder tells me they're profitable at ₹5000 per test with 10,000 tests annually, I know they're not accounting for CAC. Or they're running off grant money and calling it unit economics.
PMF requires ₹2000 test cost, ₹3500-4500 selling price, and 40%+ repeat rate. Anything else is a cash burn machine dressed up as a business.
The Government Trap
Government contracts are the heroin of healthcare startups. One big order. Large cheques. Proof of concept.
Then payment takes 8-14 months. You're funding the government.
Then specifications change. You re-engineer. Costs spike.
Then they don't repeat. They sourced you once. They'll source another vendor next time to "ensure competition."
Genomics founders who build PMF around government orders are building on sand. ICMR orders, NITI Aayog programs, state health schemes—they're validation, not traction.
Real PMF comes from private hospital networks, diagnostic chains, and paying individuals. These repeat. These have capital discipline. These don't disappear due to budget cycles.
The Stack Advantage
India Stack changes one thing: direct-to-consumer genomics now works.
Beforhand, DTC required building trust. Uploading saliva. Explaining risk. Following up.
Now: Aadhaar-verified mobile money means you can do KYC at ₹99. WhatsApp means you can follow up at zero cost. UPI means sample collection can be cash-free.
A DTC genomics player hitting PMF in India doesn't need 1M tests. It needs 10K tests per month, ₹4000 price, 35% repeat rate, and unit CAC under ₹800.
That's achievable. But not for predictive wellness tests (nobody repeats those). Only for actionable ones: pharmacogenomics, carrier screening, cancer risk.
The False Positive Graveyard
NGO pilots = worst signal. An NGO funds your test for 500 samples. Publication-friendly. Looks good on deck.
Zero commercial relevance.
Academic collaborations = similar. You get cited. You feel credible. But academics don't generate revenue.
Large trial enrollment = dangerous. 5000 samples in a CTRI trial looks massive. It feels like PMF.
It's not. It's one-time research funding. The trial ends. The cohort is gone. Nothing repeats.
Real PMF looks boring: a diagnostic center ordering 50 tests monthly for 6 months straight. A fertility clinic integrating a test into their standard workup. A pediatrician requesting carrier screening on every newborn.
No press release. No excitement. Just recurring revenue and 60% gross margin.
The Timing Lock
Genomics PMF in India requires three things to align: sequencing cost below ₹1500, clinical evidence base (published in Indian journals, not just NEJM), and integrated EHR systems in hospitals.
We have #1. We're getting #2 (CSIR labs, government research). We don't have #3 yet.
EHR integration is the constraint. When a hospital doctor can order your test from their EHR and get results in the same interface, adoption jumps 10x.
Founders waiting for EHR adoption are waiting for the right moment. Founders trying to build PMF without EHR integration are fighting gravity.
Implication for Investors and Founders
If a genomics founder can't show repeat rate >30% and unit economics positive at <₹4500 test price, they're not approaching PMF. They're burning cash and calling it validation.
If they're reliant on government contracts, they're dependent on policy luck.
If they're doing DTC for wellness (ancestry, fitness genes), stop. The repeat rate in India is 8-12%. You're a toy.
Real PMF in Indian genomics lives in actionable clinical tests, institutional buyers with protocol integration, and sub-₹2000 COGs. Everything else is a time waster.